Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid plus abiraterone versus abiraterone alone for bone mineral density in chemotherapy-naive metastatic castration-resistant prostate cancer
2013-001146-34Phase 2Active
- Sponsor
- Centre Oscar Lambret
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zoledronic acid and abiraterone in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Centre Oscar Lambret. Primary endpoint: Bone mineral density. Started Jun 2015; status: active.
02
Drugs
zoledronic acidabiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2013-001146-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001146-34.